Neorx Corporation

Other

Aletheon Pharmaceuticals, Inc.

The Dow Chemical Company

Scimed Life Systems, Inc.

Poniard Pharmaceuticals, Inc.

Kaleidos Pharma, Inc.

University of Wa

Noerx Corporation

Boston Scientific Scimed, Inc.

John M Reno

Louis J Theodore

Linda M Gustavson

Donald B Axworthy

Sudhakar Kasina

Lawrence L Kunz

Alan R Fritzberg

Richard A Klein

Ananthachari Srinivasan

David John Grainger

James C Metcalfe

Paul G Abrams

Peter L Weissberg

Jonathan F Tait

Scott Stoll Graves

Peter G Anderson

David C Anderson

David S Jones

Jeffrey N Fitzner

James A Sanderson

Becky J Bottino

Daniel R Twardzik

Thomas S Felker

Mark D Hylarides

Charles J McDonald

Eric K Yau

Alton C Morgan, Jr

Fu-Min Su

Stefan Paskell

Douglas K Pollock

Stephen W Hadley

William E Cohrs

Robert W Mallett

Andre Pernet

Marjorie A Mohler

Stephen M J Searle

Anthony R Rees

Stephen Charles Goshorn

Andrew H Henry

Jan T Pedersen

Joanne Elaine Schultz

Yukang Lin

Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.

Radiolabeled annexins

The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.

Streptavidin expressed gene fusions and methods of use thereof

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

Pretargeting methods and compounds

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

Therapeutic inhibitor of vascular smooth muscle cells

Disclosed are TGF-60  mimetics that PEGylated TGF-&agr; polypeptides and PEGylated TGF-60  related polypetides or fragments thereof.

TGF-&agr; polypeptides, functional fragments and methods of use therefor

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Clearing agents and clearance mechanisms are also discussed.

Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.

Humanized antibodies that bind to the antigen bound by antibody NR-LU-13

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.

Three-step pretargeting methods and compounds

Growing community of inventors

Brier, WA, United States of America

John M Reno